$ORGS
Orgenesis Inc. Stock $orgs

$orgs Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000149315224020662 Filed on May 20, 2024

Income Statement

Concept	2024 Q1	2023 Q1
Revenue	$141.0K	$7.044M
YoY Change	-98.0%	-2.33%
Cost Of Revenue	$492.0K	$2.722M
YoY Change	-81.93%	281.23%
Gross Profit	-$351.0K	$4.322M
YoY Change	-108.12%	-33.49%
Gross Profit Margin	-248.94%	61.36%
Selling, General & Admin	$6.056M	$4.039M
YoY Change	49.94%	20.21%
% of Gross Profit		93.45%
Research & Development	$2.370M	$3.281M
YoY Change	-27.77%	-50.39%
% of Gross Profit		75.91%
Depreciation & Amortization	$381.0K	$578.0K
YoY Change	-34.08%	21.94%
% of Gross Profit		13.37%
Operating Expenses	$8.426M	$7.320M
YoY Change	15.11%	-29.94%
Operating Profit	-$8.930M	-$3.205M
YoY Change	178.63%	-0.96%
Interest Expense	-$851.0K	-$645.0K
YoY Change	31.94%	-14.46%
% of Operating Profit
Other Income/Expense, Net	-$852.0K	-$644.0K
YoY Change	32.3%	10633.33%
Pretax Income	-$9.989M	-$4.132M
YoY Change	141.75%	3.4%
Income Tax	$16.00K	$129.0K
% Of Pretax Income
Net Earnings	-$9.765M	-$4.189M
YoY Change	133.11%	4.49%
Net Earnings / Revenue	-6925.53%	-59.47%
Basic Earnings Per Share	$0.29	$0.16
Diluted Earnings Per Share	$0.29	-$0.16
COMMON SHARES
Basic Shares Outstanding	33.18M shares	27.49M shares
Diluted Shares Outstanding	33.18M shares	26.48M shares

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$80.00K	$2.674M
YoY Change	-97.01%	138.11%
Cash & Equivalents	$80.00K	$2.674M
Short-Term Investments
Other Short-Term Assets	$1.597M	$6.184M
YoY Change	-74.18%	220.75%
Inventory	$34.00K	$128.0K
Prepaid Expenses
Receivables	$245.0K	$37.74M
Other Receivables	$0.00	$2.725M
Total Short-Term Assets	$1.956M	$49.45M
YoY Change	-96.04%	105.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.40M	$21.81M
YoY Change	-24.78%	81.88%
Goodwill	$1.211M	$8.069M
YoY Change	-84.99%
Intangibles	$8.950M	$9.430M
YoY Change	-5.09%
Long-Term Investments	$8.000K	$136.0K
YoY Change	-94.12%	-91.36%
Other Assets	$332.0K	$1.044M
YoY Change	-68.2%	-4.74%
Total Long-Term Assets	$28.96M	$43.82M
YoY Change	-33.9%	26.9%
TOTAL ASSETS
Total Short-Term Assets	$1.956M	$49.45M
Total Long-Term Assets	$28.96M	$43.82M
Total Assets	$30.92M	$93.27M
YoY Change	-66.85%	59.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.40M	$4.387M
YoY Change	273.92%	-36.72%
Accrued Expenses	$4.106M	$2.510M
YoY Change	63.59%	-29.65%
Deferred Revenue	$256.0K	$106.0K
YoY Change	141.51%	51.43%
Short-Term Debt	$626.0K	$0.00
YoY Change
Long-Term Debt Due	$2.409M	$2.376M
YoY Change	1.39%	-29.6%
Total Short-Term Liabilities	$29.03M	$13.94M
YoY Change	108.29%	-8.62%
LONG-TERM LIABILITIES
Long-Term Debt	$23.05M	$17.37M
YoY Change	32.68%	129.14%
Other Long-Term Liabilities	$377.0K	$266.0K
YoY Change	41.73%	-68.63%
Total Long-Term Liabilities	$29.44M	$20.02M
YoY Change	47.04%	137.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.03M	$13.94M
Total Long-Term Liabilities	$29.44M	$20.02M
Total Liabilities	$58.47M	$33.96M
YoY Change	72.18%	42.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$186.4M	-$125.0M
YoY Change	49.11%
Common Stock	$4.000K	$154.7M
YoY Change	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.266M	$1.266M
YoY Change	0.0%
Treasury Stock Shares
Shareholders Equity	-$27.72M	$27.67M
YoY Change
Total Liabilities & Shareholders Equity	$30.92M	$93.27M
YoY Change	-66.85%	59.33%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$9.765M	-$4.189M
YoY Change	133.11%	4.49%
Depreciation, Depletion And Amortization	$381.0K	$578.0K
YoY Change	-34.08%	21.94%
Cash From Operating Activities	-$4.441M	-$7.200M
YoY Change	-38.32%	157.88%
INVESTING ACTIVITIES
Capital Expenditures	$204.0K	$1.285M
YoY Change	-84.12%	-242.46%
Acquisitions
YoY Change
Other Investing Activities	$136.0K	-$22.00K
YoY Change	-718.18%	-96.91%
Cash From Investing Activities	-$68.00K	-$1.307M
YoY Change	-94.8%	-18.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.614M	$5.910M
YoY Change	-38.85%	590900.0%
NET CHANGE
Cash From Operating Activities	-$4.441M	-$7.200M
Cash From Investing Activities	-$68.00K	-$1.307M
Cash From Financing Activities	$3.614M	$5.910M
Net Change In Cash	-$895.0K	-$2.597M
YoY Change	-65.54%	-41.03%
FREE CASH FLOW
Cash From Operating Activities	-$4.441M	-$7.200M
Capital Expenditures	$204.0K	$1.285M
Free Cash Flow	-$4.645M	-$8.485M
YoY Change	-45.26%	348.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2023Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent		usd
CY2023Q4	ORGS	Contingent Liability Non Current ContingentLiabilityNonCurrent		usd
CY2023Q4	ORGS	Receipts On Account Of Shares To Be Allotted ReceiptsOnAccountOfSharesToBeAllotted		usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2023Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet		usd
CY2024Q1	ORGS	Credit Loss On Convertible Loan Receivable CreditLossOnConvertibleLoanReceivable		usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023Q1	ORGS	Stock Issued During Period Value Issuance Of Shares Due To Exercise Of Warrants StockIssuedDuringPeriodValueIssuanceOfSharesDueToExerciseOfWarrants		usd
CY2023Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2024Q1	ORGS	Credit Loss On Convertible Loan Receivable CreditLossOnConvertibleLoanReceivable		usd
CY2023Q1	ORGS	Credit Loss Related To Obi CreditLossRelatedToObi		usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2023Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2023Q1	ORGS	Impact To Cash Resulting From Deconsolidation ImpactToCashResultingFromDeconsolidation		usd
CY2023Q1	ORGS	Proceeds From Receipts On Account Of Shares To Be Allotted ProceedsFromReceiptsOnAccountOfSharesToBeAllotted		usd
CY2024Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts		usd
CY2023Q1	ORGS	Receipt From Germ Free ReceiptFromGermFree		usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2024Q1	ORGS	Increase Decrease In Accounts Payable Related To Purchase Of Property Plant And Equipment IncreaseDecreaseInAccountsPayableRelatedToPurchaseOfPropertyPlantAndEquipment		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue		usd
CY2023Q1	ORGS	Accounts Receivable Reconsolidation AccountsReceivableReconsolidation		usd
CY2024Q1	ORGS	Accounts Receivable Allowances For Doubtful Accounts AccountsReceivableAllowancesForDoubtfulAccounts		usd
CY2024Q1	ORGS	Exchange Rate Differences Of Accounts Receivable ExchangeRateDifferencesOfAccountsReceivable		usd
CY2023Q1	ORGS	Contract With Customer Liability Reconsolidation ContractWithCustomerLiabilityReconsolidation		usd
CY2023Q1	ORGS	Contract With Customer Liability Deconsolidation ContractWithCustomerLiabilityDeconsolidation		usd
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34430280	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	837000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	642000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	29760000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	88000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2017000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	34000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4076000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	38000	usd
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	8000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	8000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1475000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7375000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	351000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1211000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	10476000	usd
CY2023Q4	us-gaap	Assets Assets	14552000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4106000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2218000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	786000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	740000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1529000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1079000	usd
CY2024Q1	ORGS	Advance Payments On Account Of Grant AdvancePaymentsOnAccountOfGrant	2695000	usd
CY2023Q4	ORGS	Advance Payments On Account Of Grant AdvancePaymentsOnAccountOfGrant	2180000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	626000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	650000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	65000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	18000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	476000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	216000	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2344000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2670000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	29031000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16407000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1274000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	96000	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	2696000	usd
CY2024Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	20336000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	18967000	usd
CY2024Q1	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	98000	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	14000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4000	usd
CY2024Q1	ORGS	Contingent Liability Non Current ContingentLiabilityNonCurrent	4643000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	377000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	61000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	29438000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	19128000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	58469000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	35535000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	145833334	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34625349	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34338782	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	159650000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	156837000	usd
CY2024Q1	ORGS	Receipts On Account Of Shares To Be Allotted ReceiptsOnAccountOfSharesToBeAllotted	155000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	65000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	286567	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	286567	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1266000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176622000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-20983000	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	168000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-20983000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14552000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	492000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	-351000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	-2580000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2370000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3281000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	153000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	207000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3225000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9489000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6056000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13528000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8930000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19596000	usd
CY2024Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-66000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	2000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-141000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-283000	usd
CY2023Q1	ORGS	Credit Loss On Convertible Loan Receivable CreditLossOnConvertibleLoanReceivable	2688000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-852000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-681000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9989000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23248000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	129000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-10005000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-23377000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-240000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3907000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9765000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-19470000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.87
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33176657	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33176657	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26477113	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26477113	shares
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-10005000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-23377000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-61000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	41000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest	9944000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest	23418000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	240000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	3907000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9704000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19511000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-20983000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	86000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	226000	usd
CY2024Q1	ORGS	Stock Issued During Period Value Issuance Of Receipts On Account Of Shares And Warrants Allotted StockIssuedDuringPeriodValueIssuanceOfReceiptsOnAccountOfSharesAndWarrantsAllotted	2496000	usd
CY2024Q1	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	408000	usd
CY2024Q1	ORGS	Stock Issued During Period Value Issuance Of Shares Due To Exercise Of Warrants StockIssuedDuringPeriodValueIssuanceOfSharesDueToExerciseOfWarrants	20000	usd
CY2024Q1	ORGS	Impact To Cash Resulting From Deconsolidation ImpactToCashResultingFromDeconsolidation	5000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	141000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-9944000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29071000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29071000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	159000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3441000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	449000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	287000	usd
CY2023Q1	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	3671000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-19747000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9989000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9989000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-10005000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-23377000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	312000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	159000	usd
CY2024Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-66000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	381000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	578000	usd
CY2023Q1	ORGS	Credit Loss On Convertible Loan Receivable CreditLossOnConvertibleLoanReceivable	2688000	usd
CY2024Q1	ORGS	Credit Loss Related To Obi CreditLossRelatedToObi	2049000	usd
CY2024Q1	ORGS	Increase Decrease In Effect Of Exchange Differences On Intercompany Balances IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances	-200000	usd
CY2023Q1	ORGS	Increase Decrease In Effect Of Exchange Differences On Intercompany Balances IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances	179000	usd
CY2024Q1	ORGS	Net Changes In Operating Leases NetChangesInOperatingLeases	8000	usd
CY2023Q1	ORGS	Net Changes In Operating Leases NetChangesInOperatingLeases	47000	usd
CY2024Q1	ORGS	Interest Expense Accrued On Loans And Convertible Loans InterestExpenseAccruedOnLoansAndConvertibleLoans	-637000	usd
CY2023Q1	ORGS	Interest Expense Accrued On Loans And Convertible Loans InterestExpenseAccruedOnLoansAndConvertibleLoans	274000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-141000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-283000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	74000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14790000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1438000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2183000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	502000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-59000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	442000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	24000	usd
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-119000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	2000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-3000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4441000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7240000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	204000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1285000	usd
CY2024Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	139000	usd
CY2024Q1	ORGS	Repayment Of Investment In Longterm Deposits RepaymentOfInvestmentInLongtermDeposits	-2000	usd
CY2023Q1	ORGS	Repayment Of Investment In Longterm Deposits RepaymentOfInvestmentInLongtermDeposits	22000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-68000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1307000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2360000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3441000	usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	75000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5485000	usd
CY2024Q1	ORGS	Proceeds From Receipts On Account Of Shares To Be Allotted ProceedsFromReceiptsOnAccountOfSharesToBeAllotted	155000	usd
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	3000000	usd
CY2024Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	33000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	16000	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	307000	usd
CY2024Q1	ORGS	Receipt From Germ Free ReceiptFromGermFree	750000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3614000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5910000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-895000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2637000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-19000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1479000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6369000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	565000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3731000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	753000	usd
CY2023Q1	ORGS	Increase Decrease In Accounts Payable Related To Purchase Of Property Plant And Equipment IncreaseDecreaseInAccountsPayableRelatedToPurchaseOfPropertyPlantAndEquipment	14000	usd
CY2024Q1	ORGS	Extinguishment In Connection With Convertible Loan Restructuring ExtinguishmentInConnectionWithConvertibleLoanRestructuring	141000	usd
CY2023Q1	ORGS	Extinguishment In Connection With Convertible Loan Restructuring ExtinguishmentInConnectionWithConvertibleLoanRestructuring	287000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	785000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186386000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4441000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_z5xbEqu5cWF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.55pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zr2uRzCIkg44">Use of Estimates in the Preparation of Financial Statements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.55pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity, the amount of revenues and expenses, determination of loss on deconsolidation, valuation of investments, purchase price allocations, goodwill impairment, and assessment of credit losses. Actual results could differ from those estimates.</span></p>
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	141000	usd
CY2024Q1	ORGS	Cost Of Revenue Excluding Depreciation And Amortization Expenses CostOfRevenueExcludingDepreciationAndAmortizationExpenses	377000	usd
CY2024Q1	ORGS	Gross Profit Excluding Depreciation And Amortization Expenses GrossProfitExcludingDepreciationAndAmortizationExpenses	-236000	usd
CY2024Q1	ORGS	Research And Development Expense Excluding Depreciation And Amortization Expenses ResearchAndDevelopmentExpenseExcludingDepreciationAndAmortizationExpenses	2267000	usd
CY2024Q1	ORGS	Operating Expenses Excluding Depreciation And Amortization Expenses OperatingExpensesExcludingDepreciationAndAmortizationExpenses	-6046000	usd
CY2024Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-66000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	381000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-141000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-852000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9989000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142000	usd
CY2023Q1	ORGS	Cost Of Revenue Excluding Depreciation And Amortization Expenses CostOfRevenueExcludingDepreciationAndAmortizationExpenses	2486000	usd
CY2023Q1	ORGS	Gross Profit Excluding Depreciation And Amortization Expenses GrossProfitExcludingDepreciationAndAmortizationExpenses	-2344000	usd
CY2023Q1	ORGS	Research And Development Expense Excluding Depreciation And Amortization Expenses ResearchAndDevelopmentExpenseExcludingDepreciationAndAmortizationExpenses	3157000	usd
CY2023Q1	ORGS	Operating Expenses Excluding Depreciation And Amortization Expenses OperatingExpensesExcludingDepreciationAndAmortizationExpenses	-13517000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	2000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	578000	usd
CY2023Q1	ORGS	Credit Loss On Convertible Loan Receivable CreditLossOnConvertibleLoanReceivable	2688000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-283000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-681000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-681000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23248000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	200000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	70000	usd
CY2024Q1	ORGS	Recognized Loss On Deconsolidation RecognizedLossOnDeconsolidation	66000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	164000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	626000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	650000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9765000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-19470000	usd
CY2023Q1	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-3671000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9765000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23141000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33176657	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33176657	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26477113	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26477113	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.87
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2024Q1	ORGS	Contract With Customer Liability Reconsolidation ContractWithCustomerLiabilityReconsolidation	-110000	usd
CY2024Q1	ORGS	Contract With Customer Liability Deconsolidation ContractWithCustomerLiabilityDeconsolidation	60000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	10000	usd
CY2024Q1	ORGS	Contract With Customer Liability Realizations ContractWithCustomerLiabilityRealizations	4000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	141000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	88000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36183000	usd
CY2024Q1	ORGS	Accounts Receivable Reconsolidation AccountsReceivableReconsolidation	82000	usd
CY2024Q1	ORGS	Accounts Receivable Additions AccountsReceivableAdditions	150000	usd
CY2023Q1	ORGS	Accounts Receivable Additions AccountsReceivableAdditions	155000	usd
CY2024Q1	ORGS	Accounts Receivable Collections AccountsReceivableCollections	-75000	usd
CY2023Q1	ORGS	Accounts Receivable Collections AccountsReceivableCollections	-5454000	usd
CY2023Q1	ORGS	Accounts Receivable Allowances For Doubtful Accounts AccountsReceivableAllowancesForDoubtfulAccounts	-9514000	usd
CY2023Q1	ORGS	Exchange Rate Differences Of Accounts Receivable ExchangeRateDifferencesOfAccountsReceivable	-22000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	245000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21348000	usd
CY2023Q1	ORGS	Contract With Customer Liability Realizations ContractWithCustomerLiabilityRealizations	-36000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	256000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	106000	usd
CY2024Q1	us-gaap	Loss Contingency Actions Taken By Plaintiff LossContingencyActionsTakenByPlaintiff	In the Complaint, the plaintiffs are seeking that the Court issue a declaratory remedy whereby the defendants are required to pay royalties to the plaintiffs at the rate of 7% of the sales and 24% of any and all revenues in consideration for sublicenses related to any product, service or process that contain know-how and technology of Sheba and any and all know-how and technology either developed or supervised by Prof. Ferber in the field of cell therapy, including in the category of the point-of-care platform and any and all services and products in relation to the defendants’ CDMO activity.
CY2022Q1	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	10000000
CY2023Q3	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	896000	usd
CY2023Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	40140000
CY2023Q4	us-gaap	Shares Issued SharesIssued	11869600	shares

Files In Submission

Name	View Source	Status
0001493152-24-020662-index-headers.html	Edgar Link	pending
0001493152-24-020662-index.html	Edgar Link	pending
0001493152-24-020662.txt	Edgar Link	pending
0001493152-24-020662-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
logo_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
orgs-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
orgs-20240331_cal.xml	Edgar Link	unprocessable
orgs-20240331_def.xml	Edgar Link	unprocessable
orgs-20240331_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
orgs-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORGS
Orgenesis Inc. Stock $orgs

2024 Q1 Form 10-Q Financial Statement

#000149315224020662 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORGS Orgenesis Inc. Stock $orgs

2024 Q1 Form 10-Q Financial Statement

#000149315224020662 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORGS
Orgenesis Inc. Stock $orgs